{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T16:04:01Z","timestamp":1779984241007,"version":"3.53.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Asthma symptom severity can be assessed using the Asthma Daytime and Nighttime Symptom Diaries (ADSD and ANSD), which provide an accurate and standardized patient-reported option for symptom assessment during different periods of the day (i.e. daytime and nighttime), as these can vary significantly. Earlier development and validation work for the ADSD and ANSD was conducted in a broad (i.e. ranging from mild to severe) asthma population, and a US Food and Drug Administration qualification statement noted the need for further evaluation of their measurement properties, including content validity. The current study, which builds upon earlier work, was designed to ensure that the ADSD and ANSD are content-valid in patients with moderate-to-severe asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>Qualitative semi-structured concept elicitation and cognitive debriefing interviews were conducted in adults with moderate-to-severe asthma to investigate understanding of ADSD and ANSD instructions, items, recall period, response options, and concept relevance. Changes in total and item scores that were meaningful to patients were explored. General feedback on the measures was also requested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study recruited 15 patients with moderate-to-severe asthma. Content validity findings were consistent with previous studies, supporting inclusion of six core symptoms (i.e. wheezing, cough, difficulty breathing, shortness of breath, chest tightness and chest pain) as items in the ADSD and ANSD that occur during a typical day or night and impact upon patient well-being and functioning. A high level of understanding and relevance of the diary items to patients was demonstrated; instructions were confirmed to be easy to follow. In supportive analyses, meaningful levels of improvement on the ADSD and ANSD ranged from 0.5 to 3.5 and 0.2 to 5.0 respectively. Meanwhile, meaningful levels of worsening on the ADSD and ANSD ranged from 1.0 to 5.8 and 0.5 to 6.7 respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The ADSD and ANSD are content-valid measures for the measurement of daytime and nighttime symptoms and their severity in patients with moderate-to-severe asthma. Additional confirmatory studies are required to confirm the psychometric properties of the ADSD and ANSD in a moderate-to-severe population and to quantitatively estimate the threshold for meaningful improvement and worsening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-026-01079-0","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T12:44:29Z","timestamp":1779972269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Asthma daytime and nighttime symptom diaries: content validity and qualitative exploration of meaningful change in patients with moderate-to-severe asthma"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-9093","authenticated-orcid":false,"given":"Tom","family":"Keeley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Elwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agkreta","family":"Leventi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Alfonso-Cristancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"1079_CR1","unstructured":"Global Initiative for Asthma (2026) Global Strategy for Asthma Management and Prevention. Available at: https:\/\/ginasthma.org\/wp-content\/uploads\/2026\/05\/GINA-2026-Strategy-Report-WMS.pdf."},{"issue":"2","key":"1079_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1080\/02770903.2017.1316394","volume":"55","author":"LK Lee","year":"2018","unstructured":"Lee LK, Obi E, Paknis B, Kavati A, Chipps B (2018) Asthma control and disease burden in patients with asthma and allergic comorbidities. J Asthma 55(2):208\u2013219. https:\/\/doi.org\/10.1080\/02770903.2017.1316394.","journal-title":"J Asthma"},{"issue":"4","key":"1079_CR3","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/hex.13254","volume":"24","author":"K Churruca","year":"2021","unstructured":"Churruca K, Pomare C, Ellis LA, Long JC, Henderson SB, Murphy LED, Leahy CJ, Braithwaite J (2021) Patient-reported outcome measures (PROMs): a review of generic and condition-specific measures and a discussion of trends and issues. Health Expectations 24(4):1015\u20131024. https:\/\/doi.org\/10.1111\/hex.13254.","journal-title":"Health Expectations"},{"issue":"1","key":"1079_CR4","doi-asserted-by":"publisher","first-page":"14020","DOI":"10.1038\/npjpcrm.2014.20","volume":"24","author":"A Worth","year":"2014","unstructured":"Worth A, Hammersley V, Knibb R, Flokstra-de-Blok B, DunnGalvin A, Walker S, Dubois AEJ, Sheikh A (2014) Patient-reported outcome measures for asthma: a systematic review. NPJ Prim Care Resp Med 24(1):14020. https:\/\/doi.org\/10.1038\/npjpcrm.2014.20.","journal-title":"npj Prim Care Resp Med"},{"key":"1079_CR5","unstructured":"FDA. (2018) Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD). Clinical Outcome Assessments (COA) Qualification Program. Available at: https:\/\/www.fda.gov\/drugs\/clinical-outcome-assessment-coa-qualification-program\/ddt-coa-000006-asthma-daily-symptom-diary-adsd (accessed March 2024)."},{"key":"1079_CR6","unstructured":"Global Initiative for Asthma (2025) Available from: Global Strategy For Asthma Management and Prevention. https:\/\/ginasthma.org\/wp-content\/uploads\/2025\/11\/GINA-2025-Update-25_11_08-WMS.pdf."},{"key":"1079_CR7","unstructured":"FDA (2023) Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making: guidance for industry, food and drug administration staff, and other stakeholders. Draft guidance - 2023. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory. (January 2026)."},{"issue":"10","key":"1079_CR8","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1016\/j.jaip.2024.04.061","volume":"12","author":"G Mosnaim","year":"2024","unstructured":"Mosnaim G, Carrasquel M, Snedden M, Oppenheimer J, Lang D, Rathkopf M (2024) Patient-Reported Outcomes in Asthma. J Allergy Clin Immunol: Pract 12(10):2562\u20132572. https:\/\/doi.org\/10.1016\/j.jaip.2024.04.061.","journal-title":"J Allergy Clin Immunol: Pract"},{"issue":"6","key":"1079_CR9","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/thoraxjnl-2020-216421","volume":"76","author":"R Wang","year":"2021","unstructured":"Wang R, Murray CS, Fowler SJ, Simpson A, Durrington HJ (2021) Asthma diagnosis: into the fourth dimension. Thorax 76(6):624\u2013631. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-216421.","journal-title":"Thorax"},{"issue":"4","key":"1079_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jval.2016.01.007","volume":"19","author":"A Gater","year":"2016","unstructured":"Gater A, Nelsen L, Fleming S, Lundy JJ, Bonner N, Hall R, Marshall C, Staunton H, Krishnan JA, Stoloff S, Schatz M, Haughney J (2016) Assessing asthma symptoms in adolescents and adults: qualitative research supporting development of the Asthma Daily Symptom Diary. Value Health 19(4):440\u2013450. https:\/\/doi.org\/10.1016\/j.jval.2016.01.007.","journal-title":"Value Health"},{"issue":"5","key":"1079_CR11","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jaip.2021.11.026","volume":"10","author":"A Gater","year":"2022","unstructured":"Gater A, Nelsen L, Coon CD, Eremenco S, O\u2019Quinn S, Khan AH, Eckert L, Staunton H, Bonner N, Hall R, Krishnan JA, Stoloff S, Schatz M, Haughney J, Coons SJ (2022) Asthma Daytime Symptom Diary (ADSD) and Asthma Nighttime Symptom Diary (ANSD): Measurement Properties of Novel Patient-Reported Symptom Measures. J Allergy Clin Immunol: Pract 10(5):1249\u20131259. https:\/\/doi.org\/10.1016\/j.jaip.2021.11.026.","journal-title":"J Allergy Clin Immunol: Pract"},{"key":"1079_CR12","unstructured":"BEST (Biomarkers, EndpointS, and other Tools) Resource (2016). Food and Drug Administration (FDA) -National Institutes of Health (NIH) Biomarker Working Group."},{"key":"1079_CR13","doi-asserted-by":"crossref","unstructured":"Keeley TON, Dikariyanto D, Dumi V, Fromy G, Markov P, Richards F, Alfonso-Cristancho A, R (2025) Validity, reliability, and longitudinal measurement properties of the Asthma Daytime and Nighttime Symptom Diaries in patients with moderate-to-severe asthma. TBC.","DOI":"10.1186\/s41687-026-01066-5"},{"key":"1079_CR14","unstructured":"FDA (2019) March 2024: Available from: Qualification of Asthma Daytime Symptom Diary and Asthma Nighttime Symptom Diary: Patient-Reported Outcome Instruments for Measurement of Symptoms of Asthma. https:\/\/www.fda.gov\/media\/122726\/download."},{"issue":"1","key":"1079_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41687-019-0100-y","volume":"3","author":"H Staunton","year":"2019","unstructured":"Staunton H, Willgoss T, Nelsen L, Burbridge C, Sully K, Rofail D, Arbuckle R (2019) An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. J Patient Rep Outcomes 3(1):16. https:\/\/doi.org\/10.1186\/s41687-019-0100-y.","journal-title":"J Patient Rep Outcomes"},{"key":"1079_CR16","doi-asserted-by":"publisher","unstructured":"Guest G, Johnson L (2006) Johnson L How many interviews are enough? An experiment with data saturation and variability. Field Methods. 18(1):59\u201382. https:\/\/doi.org\/10.1177\/1525822X05279903.","DOI":"10.1177\/1525822X05279903"},{"issue":"7","key":"1079_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J, Litcher-Kelly L, Galipeau N, Yaworsky A, Solomon J, Shields AL (2018) Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health 21(7):839\u2013842. https:\/\/doi.org\/10.1016\/j.jval.2017.11.014.","journal-title":"Value Health"},{"issue":"3","key":"1079_CR18","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4300\/JGME-D-13-00154.1","volume":"5","author":"GB Willis","year":"2013","unstructured":"Willis GB, A.R A Jr (2013) What do our respondents think we\u2019re asking? Using Cognitive Interviewing to Improve Medical Education Surveys. J Grad Med Educ 5(3):353\u2013356. https:\/\/doi.org\/10.4300\/JGME-D-13-00154.1.","journal-title":"J Educ Chang Graduate Med Educ"},{"key":"1079_CR19","unstructured":"ATLAS.ti. (2021) Scientific software development, Germany."},{"issue":"2","key":"1079_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s43441-024-00739-x","volume":"59","author":"M Reaney","year":"2025","unstructured":"Reaney M, Shih V, Wilson A, Byrom B, Medic N, Oberdhan D, Mamolo C, Majumder M (2025) A Consistent Lack of Consistency: Definitions, Evidentiary Expectations and Potential Use of Meaningful Change Data in Clinical Outcome Assessments Across Stakeholders. Results from a DIA Working Group Literature Review and Survey. Ther Innov Regul Sci 59(2):337\u2013348. https:\/\/doi.org\/10.1007\/s43441-024-00739-x.","journal-title":"Ther Innov Regul Sci"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-01079-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01079-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01079-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T15:17:40Z","timestamp":1779981460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-01079-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1079"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-01079-0","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles outlined in the Declaration of Helsinki. Institutional review board approval for the qualitative interview was obtained from Western Copernicus Group Independent Review Board (approval code 45168598). Ordinal patient identification numbers were assigned herein to provide context for quotations while maintaining anonymity.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Institutional review board approval for the qualitative interview was obtained from Western Copernicus Group Independent Review Board (approval code 45168598).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable; individual patient data is included in the manuscript but has been anonymized.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TK is an employee of GSK and holds financial equities in GSK; KF, HE, AG, SL, and AL are\/were employees of Adelphi Values, a consulting company which received research funds from GSK to conduct this study but did not receive payment for manuscript development; RA-C was an employee of GSK at the time of the study and may hold financial equities in GSK.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}